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ABSTRACT:
BACKGROUND: Much of our understanding of normal liver pathophysiology
comes from studying patients with liver disease who remain undiagnosed after a
comprehensive workup.

Searching for diagnoses among such cohorts has

benefits both for the underserved patients with idiopathic liver disease, but also
for science as a whole. Unbiased genomic analysis of patients with undiagnosed
disease has yielded remarkable results, including clinically actionable diagnoses
in children and adults, as well as the discovery of novel genetic diseases. Thus,
we posit that among pediatric patients with undiagnosed liver disease, there may
be previously unrecognized Mendelian causes.
METHODS: We report a 2.5 year old with unexplained congenital chronic
diarrhea, coagulopathy, fat-soluble vitamin deficiency, cholestasis and liver
fibrosis. Exome sequencing and analysis was performed. Once a gene of interest
was revealed, its expression at the mRNA level was assessed in colon tissue
biopsy of the proband.
RESULTS: Exome sequencing uncovered a previously unidentified homozygous
premature termination mutation (p.Gln186*) in SLC51A, encoding for the alpha
subunit of the heteromeric organic solute transporter alpha-beta (OSTα-β), an
important contributor to intestinal bile acid reabsorption in the enterohepatic
circulation. Gene expression assay showed absence of SLC51A and detectable
SLC51B mRNA transcripts in the proband’s colon tissue.
CONCLUSION: This study identifies a novel genetic digestive disorder due to
OSTα deficiency. Homozygous loss-of-function mutation in SLC51A causes
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chronic diarrhea, features of cholestasis, and liver fibrosis. Our findings further
contribute to the body of evidence showing the importance of studying patients
with undiagnosed disease, and the utility of whole exome sequencing as a
powerful tool in clinical diagnosis and scientific discovery.
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INTRODUCTION
Despite major advances in the diagnosis and treatment of viral causes of
hepatitis, the burden of chronic liver disease is rising worldwide, with end-stage
liver disease ranking as the 11th leading cause of death worldwide in 2016 (1-3).
As of 2018, over 4.5 million adults in the U.S. are diagnosed with chronic liver
disease (4). The number of people affected by these diseases underscores the
importance and urgency of understanding more about the pathophysiology of
liver disease.

The liver is a complex, multi-purpose organ that serves as a hub of anabolism,
catabolism and endocrine signaling, and its role in each of these areas remains
incompletely understood. Our current knowledge gaps are reflected not only in
our lack of treatments for metabolic diseases such as non-alcoholic fatty liver
disease (NAFLD), but also in the number of patients with liver disease of
unknown cause. Amongst various cohorts of patients with cirrhosis, 5-30% are
labeled as “cryptogenic,” meaning that after exhaustive work-up, there is no
known cause of their end-stage liver disease (5).

The prevalence and burden of idiopathic liver dysfunction is underestimated
based on cryptogenic cirrhosis data alone, as it may remain asymptomatic until
the first decompensation arises, such as ascites, esophageal variceal
hemorrhage and/or hepatic encephalopathy. Elevated transaminases of
unknown etiology have been reported in up to 2.5% of the general adult
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population in Taiwan (6). A study of 254 adults with 6 months of persistently
abnormal liver function tests identified no etiology for such abnormalities in nearly
20% (7). These studies demonstrate the gaps in knowledge in our
understanding of the pathogenesis of liver disease, highlighting the importance of
basic science and translational research to investigate the mechanisms of liver
disease.

Role of human genetics in healthy and diseased liver
Historically, genetic studies of patients with liver disease have played a large role
in our understanding of liver physiology (8). In the 1990s, genetics provided us
with a molecular-level understanding of copper and iron-metabolism from
studying patients with Wilson Disease and hemochromatosis, respectively (8, 9).
Studying patients with Dubin-Johnson and Rotor Syndrome further elucidated the
transporters involved in the flow of bile from the liver into the biliary tree and
digestive tract (10, 11). By applying unbiased genomic analysis to undiagnosed
pediatric liver disease, the Vilarinho laboratory has discovered recessive
mutations in DGUOK, ACOX2, and KIF12 as novel Mendelian causes of noncirrhotic portal hypertension (12), bile acid synthesis disorder (13), and
cholestatic liver disease (14), respectively. Within the last 35 years, nearly 100
cirrhosis-causing genes have been discovered and added to the Online
Mendelian Inheritance in Man (OMIM) database (Figure 1).
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Figure 1. Overview of the rising number of liver disease-causing genes discovered over
the past 35 years. The graph depicts the approximate number of liver disease-causing
genes identified within the last three decades based on the Online Mendelian
Inheritance in Man (OMIM) database descriptive entries (last accessed in August 31,
2019). Specifically, we analyzed results from text query “cirrhosis” in the OMIM
database. These genes were further investigated in Pubmed to find the original
discovery date of the gene and liver-related phenotype. Somatic mutations, gene
associations, and cases in which there was limited evidence of liver disease-gene
causality were not included in this graph.

Despite major advances in human genetics since the completion of the human
genome project nearly 20 years ago, the majority of genes still have partially or
completely unknown function in normal human physiology. The putative
functions of the majority of genes have been extrapolated from orthologous
genes in model organisms such as yeast and mice (15). However, there are
limits to understanding human physiology from orthologous organisms. For many
genes there are significant differences in expression between humans and
organisms such as mice, limiting our ability to draw meaningful conclusions about
human disease from such experimental models. Moreover, many human gene
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functions have been predicted through computational, in silico inferences rather
than functional studies in model organisms (16).

Studying human phenotypes of monogenic disorders is a powerful tool for
understanding a gene’s function. According to OMIM, mutations in
approximately 20% of human protein-encoding genes have been shown to cause
pathologic phenotypes, shedding light on their role in human health and disease
(17). Given the liver’s multipurpose role in the body, understanding the
pathophysiology of the liver has broadly generalizable medical benefits.

The enterohepatic circulation
All orally ingested drugs must pass through the liver before entering systemic
circulation, and over half of the most widely prescribed drugs in the U.S. are
metabolized predominantly in the liver (18). Understanding enterohepatic
circulation on a molecular level is important to optimize medication efficacy and
mitigate toxicity (19). Enterohepatic circulation refers to the chemical and
physical recycling of bile. Bile is synthesized in the liver, excreted into the biliary
ducts and released into the small intestine upon ingestion of a meal, after which it
is reabsorbed by enterocytes and transported back to the liver through the portal
vein. This circulation of bile enables the fat-soluble nutrients and pharmacologic
agents from the alimentary track to be absorbed in the small intestine and colon
and introduced to the portal vein and first-pass metabolism in the liver. As one of
the body’s major sites for xenobiotic metabolism, the liver also secretes several
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toxins, including mercury (20), as well as pharmacological agents, such as
mycophenolate glucuronide, into bile, such that they can be excreted in feces or
metabolized and reabsorbed by the body (21). Each of these steps is mediated
on a molecular level by transporters, whose known locations are summarized in
Figure 2.

Figure 2. Schematic representation of enterohepatic circulation highlighting major known
bile acid transporters. Bile acids are depicted by yellow circles labeled “BA”. Because
the OSTα-β transport of bile acids is bidirectional and diffusion-dependent, bidirectional
arrows of different sizes are used to depict the flow of bile acids, with larger arrows
indicating concentration-dependent flow in individuals without cholestasis. Image
adapted from Ballatori et. al. 2009, Frontiers in bioscience (22).
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Organic solute transporter α-β
Among the enterohepatic bile acid transporters, the heterodimer organic solute
transporter α and organic solute transporter β (OSTα-β) serves as an example of
a transporter that has been well-characterized in model organisms, with
emerging relevance to human disease. OSTα-β is a heteromeric organic solute
and steroid transporter that was initially discovered in 2001 in the liver of a
marine vertebrate, Leucoraja erinacea (the little skate) (23). Two years later the
human orthologs of these proteins, encoded by SLC51A and SLC51B were
described (24). The former encodes for a 340–amino acid protein with seven
transmembrane domains whereas the latter encodes for a 128–amino acid
protein with a single transmembrane domain (24). Expression of both subunits is
essential for transporter stability and delivery to the basolateral membrane of a
variety of epithelial cells, and loss of expression of either subunit results in loss of
transporter activity (23).

OSTα-β and the apical sodium-dependent bile acid transporter (ASBT) play
important roles in the enterohepatic bile acid circulation. ASBT mediates sodiumdependent bile acid uptake across the luminal membrane of the enterocyte while
transport across the basolateral membrane to the portal vein is facilitated by
OSTα-β (25). In humans, OSTα-β is also expressed in the basolateral membrane
of hepatocytes, cholangiocytes, colonocytes and renal proximal tubule cells, as
well as testes, ovaries and adrenal glands (22, 24, 25). While recessive
mutations in SLC10A2, which encodes ASBT, have been reported to cause a
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human primary bile acid malabsorption disorder (26), and OSTβ deficiency has
been identified in two siblings with chronic diarrhea and features of cholestasis
with SLC51B mutations (27), no human disease has yet been ascribed to
mutations in SLC51A. However, OSTα-β has recently received interest from the
pharmaceutical industry, as its inhibition has been proposed as a potential
mechanism of drug-induced liver injury (28). Moreover, OSTα-β has been
implicated in playing a protective role in chronic cholestatic liver disease, as
hepatic expression of these proteins are strongly up-regulated in patients with
cholestatic liver injury (29).

Populations at greatest risk of genetic disease and highest potential for
gene discoveries
Historically, studying patients with undiagnosed diseases among populations with
a high rate of autozygosity, has led to the discovery of gene functions and novel
genetic diseases, including Tay-Sachs in the Ashkenazi Jewish population or
Progressive Familial Intrahepatic Cholestasis Type 1 in the Old Order Amish (30,
31), among many others. Children born of consanguineous unions are at higher
risk of having recessive genetic diseases due to higher rates of autozygosity
(32), with some studies estimating first-cousin marriage to have doubled risk
compared to the general population (33). Other causes of high autozygosity
include geographic isolation and endogamy (marriage within an ethnic or
religious group). One of the countries with the highest rates of consanguinity is
Pakistan. Given that up to 62% of marriages are consanguineous in certain
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regions of the country (34), there is predicted to be a high burden of genetic
disease.

Whole Exome Sequencing
Whole Exome Sequencing (WES) has emerged as a powerful and cost-effective
tool in gene discovery and clinical diagnosis (35-37).

WES captures and

sequences protein-coding segments of DNA, known individually as exons, and in
aggregate as the exome, which is predicted to encode for ~20,000 proteins.
Although the exome makes up 1-2% of the human genome, variants in exons are
suspected to account for 85% of genetic diseases (35). WES is comprised of
two components, a wet laboratory process, and a computational pipeline,
summarized in Figure 3.

The wet laboratory process of WES begins with

extraction of genomic DNA from biological samples (e.g., blood, buccal swabs,
saliva, paraffin-embedded tissue, etc.), followed by selective capture and
amplification of coding DNA (exons), and its massive parallel sequencing. The
computational component of the WES pipeline transforms the raw sequence data
into a dataset that can be analyzed for disease-causing genetic variants. WES
data is aligned to and compared with the human reference genome, calling any
variation from the reference sequence. In a process known as “annotation”, each
variant’s minor allele frequency, chromosome and genome position, resulting
amino acid change, predicted deleteriousness based on in silico calculations,
and previous reports of pathogenicity are determined. Annotation data is then
used to prioritize variants as disease-causing candidates based largely on the
rareness and (predicted or known) pathogenicity of the variant.
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Figure 3. Overview of whole-exome sequencing pipeline. SNV, single nucleotide variant;
Indels, insertion and deletions. BWA, Burrows-Wheeler Aligner (38); GATK, Genome
Analysis ToolKit (39); Annovar, ANNOtate VARiation (40). Adapted from Goh and Choi,
2012, Genomics and Bioinformatics (41).

WES has a reported diagnostic yield of 11-34% among cohorts of undiagnosed
patients who had previously exhausted extensive workups (42-45).

These

diagnoses are significant not only to the patients suffering from these rare
diseases, but often to the scientific community as a whole. When analyzing 160
patients through the NIH Undiagnosed Disease Network, novel associations
were discovered between a gene and a known disease in 3.5% of patients, and
novel genetic diseases were characterized in 1% of patients (45). Since 2014,
200-300 novel genetic diseases have been added to OMIM annually, with nearly
1000 novel genotype-phenotype relationships reported from 2016 up to now (46).
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Over the past 10 years mutations in numerous genes have been discovered to
cause cholestasis and other liver phenotypes, including genes with exclusive or
predominant liver involvement and those with hepatic and extra-hepatic
syndromes (13, 14, 47, 48). Here, by combining deep phenotyping with unbiased
WES to study patient(s) suffering from liver disease of unknown etiology, we
identified the first case of OSTα deficiency in a child with elevated liver
transaminases, cholestasis and congenital diarrhea of unknown etiology.
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STATEMENT OF PURPOSE
To identify novel genetic liver disorder(s) by combining deep phenotyping with
unbiased WES in evaluation of patient(s) with unexplained liver disease.
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PATIENTS AND METHODS
Human subjects
The proband and his family members were recruited for study. Written informed
consent was provided for all participants. This study was approved by the
institutional review boards of The Children’s Hospital and the Institute of Child
Health in Lahore, Pakistan, and the Yale University.

DNA isolation, exome capture and sequencing
Genomic DNA was isolated from dried blood spots using standard procedures;
the xGen capture kit from IDT was used for exome capture, and 100 base pairedend sequencing was performed on the Illumina HiSeq platform.

Exome sequencing analysis
WES data was aligned to the human reference genome (hg19) using BWA-MEM
(38). Genome analysis tool kit (GATK) was used to identify nucleotide bases in
the proband that differ from the reference genome, in a process known as
“variant calling” (39). Variants with minor allele frequency of 0.01 or less were
annotated with amino acid change consequences, predictions of deleteriousness,
and minor allele frequencies utilizing Annovar (40). Allele frequencies were
determined using the Genome Aggregation Database (gnomAD) which contains
125,748 exomes and 15,708 genomes from a diverse array of disease-specific
studies as well as unrelated individuals sequenced for population genetics
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studies (last accessed on January 28, 2020). Rare mutations were subsequently
prioritized by predicted deleteriousness. Prioritized mutations include nonsense,
frameshift, start-lost or gained, splice site variants, and deleterious missense
variants. Functional impact of protein-altering missense variants was predicted
utilizing MetaSVM or Polyphen-2 (49), such that variants predicted to be benign
were filtered out. Both MetaSVM and Polyphen-2 predictions are computed
based on many factors, including sequence conservation among orthologous
organisms, and protein structure modeling (49, 50). MetaSVM has been known
to weigh conservation more heavily, based on the assumption that highly
conserved regions are essential to healthy human physiology while poorly
conserved regions may be less essential to protein structure and function (50).
The alignment and predicted result of these variants of interest were manually
confirmed utilizing BLAT, an alignment script embedded within the UCSC Human
Genome Browser (51).

Principal Component Analysis
Ancestral origin was inferred using principal component analysis (PCA) of tagged
single-nucleotide polymorphisms (SNPs). Tag SNP genotypes represent a
region of the genome within a linkage disequilibrium block and are likely to be
shared by a given subpopulation. Using EIGENSTRAT software, we performed
PCA on tag SNPs extracted from our proband’s exome sequence combined with
tag SNPs from HapMap project subjects of various ethnicities to infer the
ancestry of our proband (52).
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Inbreeding coefficient
Inbreeding coefficients were estimated by identifying homozygous by descent
(HBD) using the software BEAGLE 3.2, as described previously (53).

Sanger sequencing
The nomenclature of the SLC51A variant is based on the National Center for
Biotechnology Information reference sequence NM_152672. Sanger sequencing
of the identified SLC51A mutation p.Gln186* was performed by PCR
amplification of genome DNA of the proband, his parents and his sibling using
the following primers: forward 5’-AGTGGGAGACCAAGAGGGTT-3’, reverse 5’CCTTACTCCCGGCTTACGTC-3’.

mRNA gene expression TaqMan assays
RNA was extracted from formalin fixed paraffin-embedded (FFPE) samples of
proband’s colonic biopsies and unrelated normal-appearing colonic tissues using
Beckmann Coulter agencourt FormaPure RNA kit (Ref#C19158). The
superscript IV VILO kit was used for cDNA synthesis. Gene expression of
GAPDH (Hs99999905_m1), SLC51A (Hs00380895_m1), and SLC51B
(Hs01057182_m1) was assessed using ABI TaqMan assays.
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Bile acid measurement
Bile acid concentrations in dried blood spots were measured using liquid
chromatography – tandem mass spectrometry (LC-MS/MS) with stable-isotope
internal standards as described previously (13, 54).
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STATEMENT OF WORK
Dr. Vilarinho conceptualized and designed the project and under her guidance I
performed the computational analysis for the proband’s exome (including exome
sequencing analysis, principal component analysis and identity by descent
analysis), Taqman gene expression analysis, reviewed and integrated our results
with the current literature and wrote this thesis.
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RESULTS
Case Report
A two and a half year-old Pakistani male, born from a first cousin union, was
found to have abnormal liver function tests (Table 1). He was born at full term,
with no complications and normal weight, height and head circumference. Since
birth, he has suffered from chronic malabsorptive diarrhea of unclear etiology
complicated by failure to thrive. Of note, the patient was exclusively breast fed
during his first year of life, with introduction of food only at 1 year of age. His past
medical history is also significant for easy bruising, with two episodes of
prolonged bleeding that required blood transfusions (one at the circumcision site
at 1.5 months of age, and another at a vaccination site at 6 months of age), and
two hospitalizations for respiratory infections of unclear etiology. Developmental
milestones include social smile at 2 months, delayed sitting without support at 10
months of age and walking at 18 months of age attributed to motor delay in the
setting of malnutrition due to underlying disease. At one year of age, he was
started on nutritional supplementation, including a soy-based formula and fatsoluble vitamin (A, D, E, K), after which his weight and height improved
significantly. However, at age two and a half he was found to have elevated
aminotransferases and alkaline phosphatase (Table 1). A comprehensive
evaluation was unrevealing of the etiology of liver dysfunction (Table 2). An
abdominal ultrasound showed a mildly enlarged liver with normal liver
echotexture and a mildly enlarged spleen spanning 8.6 cm. Liver biopsy at 3.8
years old revealed a lobular architecture suggestive of early cirrhosis with portal
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and peri-portal fibrosis and many thin fibrous septa (Figure 4A,B). Portal areas
showed only minimal lymphocytic inflammation, no interface activity and patchy
mild bile ductular proliferation highlighted by cytokeratin 7 and cytokeratin 19
immunostains (Figure 4C,D). Bile ducts were missing in some of the portal tracts,
but not sufficiently to fulfill the criteria for bile duct paucity (Figure 4E). The
hepatocytes were otherwise unremarkable, except for rare foci of subtle
hepatocytic cholestasis (Figure 4F). Duodenal and colonic biopsies showed no
significant abnormality (Figure 5A,B). At his most recent clinic visit, the proband
was 5 years-old and he had started taking ursodeoxycholic acid and fat-soluble
vitamins. Although with time his growth had normalized, his coagulopathy had
resolved and he had not developed any new liver or gastrointestinal-related signs
or symptoms; he continued to have persistently elevated transaminases, direct
bilirubin and GGT levels (Table 1).
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Table 1. Clinical and laboratory findings in the proband who harbors a
homozygouspremature termination mutation (p.Gln189*) in SLC51A.

Laboratory Test

Reference

Proband’s Age in Years
2.5
3.8
4
126 (H)
112(H)
98 (H)
227(H)
126 (H)
117 (H)
0.7/n.a.
1.6
1.8/1.2
(H)/n.a.
(H)
n.a.
n.a.
n.a.
708 (H) 1320 (H) 661 (H)
3.1 (H)
1.6 (H)
1.6 (H)
8.7
n.a.
n.a.

5
66 (H)
90 (H)
2.3/1.9
(H)
104 (H)
268
1.1
28*

n.a.
n.a

3.7
n.a

n.a.
140

n.a.
n.a.
n.a.

n.a.
n.a.
n.a.

32
93
77

n.a.
n.a.

n.a.
n.a.

0.02
0.11

n.a.
n.a.

n.a.
n.a.

0.11
0.33

n.a.

n.a.

0.06

n.a.

n.a.

0.07

AST (U/L)
15-40
ALT (U/L)
4-25
Bilirubin total/direct
0.1(mg/dL)
1.2/<0.3
GGT (U/L)
5–32
ALP (U/L)
100–320
INR
0.9-1.1
Vitamin D, 25-OH
16-65
(ng/mL)
Albumin (mg/dL)
3.5-5.5
n.a.
Total Cholesterol
<170
n.a.
(mg/dL)
HDL (mg/dL)
> 35
n.a
LDL (mg/dL)
<110
n.a.
Triglycerides (mg/dL)
32-116
n.a.
Bile Acids Measured in DBS samples**
Cholic acid
0.003-0.19
n.a.
#
Dihydroxycholanoates
0.09-2.21
n.a.
(µM)
Glychocholic acid (µM) 0.005 -2.52
n.a.
Glycodihydroxycholano 0.22-4.16
n.a.
-ates## (µM)
Taurocholic acid (µM)
0.001n.a.
0.612
Taurodihydroxycholano
ates### (µM)

0.03-0.43

n.a.

*on vitamin D supplement; **prior to initiation of ursodeoxycholic acid supplement
#
Chenodeoxycholic acid + deoxycholic acid; ##Glycochenodeoxycholic acid +
glycodeoxycholic acid; ###Taurochenodeoxycholic acid + taurodeoxycholic acid
n.a., not available; H, high; DBS, dry blood spots
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Table 2. Summary of laboratory tests performed as part of the
comprehensive evaluation for abnormal liver function and chronic
diarrhea prior to pursuit of whole-exome sequencing.
Labs
HAV, HBV, HCV, CMV, EBV, HIV, VZV,
ParvoB19, Rubella, HSV-1, HSV2
pANCA
cANCA
Anti-LKM1
Anti-smooth muscle antibodies
Coomb’s test
Iron (mg/dL)
Ferritin (ng/mL)
TIBC (mg/dL)
Αlpha-1 antitrypsin (mg/dL)
IgA (g/L)
IgE (IU/mL)
IgM (mg/dL)
Anti-tissue transglutaminase IgA (U/mL)

Proband’s Value
(Normal range)
negative
negative
negative
negative
negative
negative
85 (50–120)
229.8 (7–140)
260 (250–425)
162 (100-300)
0.62 g/dL (0.27-1.95)
205.4 (<60)
89 (24-210)
0.9 (<7.0)

Anti-tissue transglutaminase IgG (U/mL)
3.0 (<6.0)
Cholesterol (mg/dL)

Triglyceride (mg/dL)

Total: 140 (<170)
HDL: 32
LDL: 93
77 (32-116)
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Figure 4. Liver histology of the proband with undiagnosed cholestatic disease. Liver
biopsies sectioned from the proband with (A) haematoxylin and eosin (HE) stain showing
distorted lobular architecture and expanded portal areas with mild ductular proliferation.
(B) Trichrome stain showing portal and periportal fibrosis along with many thin fibrous
septa. Nodularity of the lobular architecture and features of early cirrhosis are obvious at
this magnification. (C) Cytokeratin 7 immunostain highlights the portal tracts and shows
mild bile ductular proliferation in most of the portal areas. (D) Higher magnification of
cytokeratin 19 immunostain of one of the portral tracts showing presence of two bile duct
profiles (arrows). (E) Two portal areas are depicted; one with few bile ductular profiles
(arrow) and one devoid of any bile ducts (circle) The portal areas show only minimal
lymphocytic inflammation and no interface activity. Hepatocytes are otherwise
unremarkable. (F) Higher magnification of periportal area showing rare foci of subtle
hepatocytic cholestasis. Scale Bars shown in lower right corner of each figure,
measuring 100 µm in figure 4 A, B, and C and 50 µm in the remaining panels. As
published in part in Gao et. al. 2019 (55)
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Figure 5. Duodenal and colonic mucosa of the proband. (A) H&E stain of duodenal and
(B) colonic mucosa showing no significant histological abnormality. Scale Bars, 50 µm.
As published in part in Gao et. al. 2019 (55)
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Homozygous loss-of-function mutation in SLC51A
The proband’s exome was sequenced to a mean depth of 44 independent reads
per targeted base, with 96% of targeted bases having more than eight
independent reads, providing high-confidence calling of homozygous and
heterozygous variants across the exome (Table 3). Calculated inbreeding
coefficient of 0.067 was consistent with first-cousin union (Figure 6A). We thus
focused our analysis on rare homozygous variants. Consistent with
consanguinity, the proband harbors 23 rare homozygous protein-altering variants
(Table 4). Twenty-two of these resulted in missense variants. None of these
missense variants were predicted to be damaging by MetaSVM and were
therefore unlikely to be the cause of disease in this child. The other homozygous
mutation led to a premature termination at codon 186 in SLC51A (NM_152672,
c.556C>T, p.Gln186*), which encodes the solute carrier organic soluble
transporter alpha (OSTα), a known transporter with an important role in bile acid
homeostasis (25). This variant allele is extremely rare, with an overall allele
frequency in gnomAD of 4 x 10-6 with only 1 instance of this variant among more
than 251,400 alleles sequenced from diverse populations, including South Asians
(Table 4). Sanger sequencing confirmed the homozygous variant in the proband
and showed the heterozygous carrier state of both his parents and an unaffected
sister (Figure 6B). Eigenstrat showed ethnic clustering of the proband to South
Asian populations (Figure 7). The predicted amino acid change from this variant
occurs in the fourth of eight transmembrane domains of the OSTα transporter
(Figure 8).
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Table 3. Quality metrics of proband’s exome.
Metric

Value

Mean independent reads per targeted base

44

Read length, bp

100

Percent of bases mapping to genome

99.95

Percent of targeted bases with > 8 independent reads

93.8

Mean error rate, %

0.25
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B

Figure 6. Pedigree and Sanger sequencing of the affected proband and his
unaffected family members. (A) Pedigree of the proband’s family with affected
and unaffected subjects shown in black and white respectively; consanguineous
union is represented by a double line. SLC51A alleles are denoted as WT or
Mut. (B) Sanger sequencing chromatogram of the nonsense mutation in the
proband and his unaffected parents and siblings are shown. The SLC51A
mutation at chr3:195955714 C>T (NM 152672), resulting in the 186 codon
change from CAA (Glutamine) to TAA (stop codon) is homozygous in the
proband and heterozygous in the unaffected parents and sister. Figure as
published in Gao et. al. 2019 (55)
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Table 4. Rare homozygous protein-altering variants identified in the proband.
Gene

Chr:Position

AA Change

SLC51A

3:195955714

Gln186*

MetaSVM
score
a
prediction
truncating

UAP1

1:162557401

Asn324Ser

-1.019 (T)

6.01E-05

MROH2A

2:234698170

Tyr102Asn

-1.071 (T)

1.19E-05

UTRN

6:144750869

Asn283His

-1.036 (T)

2.16E-4

PCM1

8:17868817

Arg504Ser

-0.969 (T)

3.88E-03

6.53E-03 (NonFinnish European)

CYP7A1

8:59404935

Pro398Ala

-0.912 (T)

3.36E-03

6.33E-03 (Finnish
European)

BHLHE22

8:65493627

Gly94Ser

-0.084 (T)

1.69E-03

2.84E-03
(Ashkenazi Jewish)

BICD2

9:95481848

Ala360Val

-1.04 (T)

4.60E-05

FAM208B

10:5790722

Phe1780Val

-0.926 (T)

6.0E-04

SHOC2

10:112724729

Thr205Ala

-0.919 (T)

5.18E-05

NELL1

11:21594825

Ser704Asn

-0.536 (T)

3.39E-04

NCKAP5L

12:50189841

Pro316Leu

-1.098 (T)

1.42E-05

C14orf93

14:23467689

Arg182Trp

-0.818 (T)

1.32E-04

ACIN1

14:23549416

Ser394Arg

-1.063 (T)

4.70E-04

BCL11B

14:99723953

Asp94Glu

-1.03 (T)

5.49E-04

ISL2

15:76630847

His168Pro

-0.288 (T)

2.11E-04

Arg19Gly

Not
available

3.26E-04

MESDC2

b

15:81282077
15:81282078

gnomAD
(overall)

gnomAD
(highest frequency)

3.98E-06

6.152E-05 (African)
3.01E-04 (East
Asian)
1.20E-04 (South
Asian)
1.76E-03 (South
Asian)

1.68E-04 (South
Asian)
4.77E-03 (South
Asian)
3.92E-04 (South
Asian)
2.68E-03 (South
Asian)
1.23E-04 (South
Asian)
9.63E-04 (South
Asian)
3.69E-03 (South
Asian)
4.48E-03 (South
Asian)
2.53E-03 (South
Asian)
2.52E-03 (South
Asian)

6.5E-05 (South
Asian)
5.53E-03 (South
LGALS16 19:40151145
Asn138Lys
-0.983 (T) 1.18E-03
Asian)
1.94E-04 (South
SFI1
22:31999780
Arg537His
-1.027 (T) 4.02E-05
Asian)
DOCK11
X:117788680
Gln1604Arg -1.047 (T) 0
0
MAGEC3
X:140969340
Pro223Thr
-1.038 (T) 0
0
a
MetaSVM scores missense variants on a scale of -2 to 3, with scores <0 predicted to be
tolerated (T) and scores > 0 predicted to be damaging (D)
b
MESDC2 variants are consecutive nucleotide changes on the same allele and therefore
MetaSVM score cannot be calculated. Polyphen HumVar for this variant was predicted to
be benign (49). AA, amino acid; Chr, chromosome
ZCCHC2

18:60241937

Val875Leu

-1.115 (T)

8.02E-06

28

Figure 7. Principle component analysis of the proband with homozygous p.Gln186*
mutation in SLC51A (light blue star) shows that the proband cluster with individuals of
South Asian ancestry from the HapMap project (light blue circles).
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Figure 8. Schematic depiction of the location of the proband’s terminating mutation in
OSTα. OSTα is a seven-transmembrane protein, depicted in green. The red triangle
depicts the location of the terminating mutation in the proband, in the fourth
transmembrane subunit. An early termination mutation at this location would result in a
non-functional protein, and likely mRNA decay. The second subunit of the OSTα-β
transporter, OSTβ, is a single-transmembrane protein, depicted in grey. Expression of
both subunits has been shown to be necessary for the functionality of this bile acid transporter
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SLC51A, but not SLC51B, is absent in the proband’s colon
To confirm absence of SLC51A expression in proband tissues, RNA was
extracted from FFPE colonic mucosal tissue of the proband and two controls.
The controls colons were normal-appearing, from one adult and one child without
known liver or colonic disease. While SLC51A and SLC51B transcripts were
detected in the normal-appearing colonic mucosal control, the proband’s colon
tissue showed only SLC51B expression with undetectable mRNA expression of
SLC51A (Figure 9). This pattern of expression was consistent with the above
recessive premature termination mutation in SLC51A leading to mRNA decay.

Figure 9 Gene expression of SLC51A and SLC51B relative to GAPDH in proband and
control colon tissues. N. D.- not detected. Figure as published in Gao et. al. 2019.

31
The proband’s blood spot bile acid concentrations were not elevated
Given that the proband had underlying cholestasis while also lacking a major
transporter that returns bile acids to the portal systemic circulation and the liver,
we quantified serum bile acid levels. Analysis of the bile acid concentrations in
the proband’s blood spot by LC-MS/MS, prior to initiation of ursodeoxycholic
acid, showed that all bile acid concentrations were within the normal range in
spite of underlying cholestasis (Table 1).
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DISCUSSION
Our findings provide the first demonstration of human OSTα deficiency in a child
with elevated liver transaminases, elevated GGT cholestasis, liver fibrosis and
congenital diarrhea. The evidence implicating SLC51A as the cause of the
proband’s phenotype is strong.

First, the proband harbors a homozygous mutation for an extremely rare
premature termination mutation in SLC51A, representing the first human
recessive loss-of-function variant reported in this gene. Second, there is absence
of SLC51A mRNA expression in the proband’s colon tissue, consistent with his
genotype. Third, from a clinical standpoint, the proband’s history of chronic
diarrhea, evidence of coagulopathy and deficiency of fat-soluble vitamins, failure
to thrive, cholestasis and elevated hepatic transaminases are all consistent with
a defect in bile acid metabolism. OSTα-β is a bi-directional, diffusion-dependent
bile acid transporter. While under normal physiological conditions it is thought to
reabsorb recycled bile acids from the portal vein to the liver, it has been
suggested that under pathological conditions, OSTα-β transporters might be
hepatoprotective by exporting bile acids into the plasma to decrease toxic levels
in the liver (29, 56). This is supported by the fact that in cholestatic disorders,
such as primary biliary cholangitis and biliary obstruction, hepatic expression
OSTα-β is increased (29). Additionally, OSTα-β inhibition has been proposed as
a potential mechanism of drug-induced liver injury (DILI). Several drugs
associated with cholestatic DILI were shown to inhibit OSTα-β activity in vitro by
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greater than 25% (28). Fourth, human deficiency for OSTβ, which forms a
heterodimer with OSTα in the active transporter, has been recently described in
two siblings who also presented with malabsorptive diarrhea and features of
cholestasis (27, 57). Collectively, these three patients with either OSTα
deficiency or OSTβ deficiency, all have elevated transaminases (ALT>AST),
elevated GGT, and low-normal circulating bile acids.

Aside from the SLC51A variant, the only other rare variant our proband harbors
in a gene associated with the bile acid pathway is CYP7A1, which encodes for
cholesterol-7-α hydroxylase. This enzyme is responsible for the initial step in
bile-acid metabolism (58). However, the CYP7A1 variant harbored by our
proband results in an amino acid substitution predicted to be benign by
MetaSVM. Furthermore, the phenotype of cholesterol-7-α hydroxylase deficiency
is characterized by hypercholesterolemia with an average total cholesterol level
above 300 mg/dL among CYP7A1 homozygotes, with no signs of cholestasis, no
abnormalities in liver function tests, and no diarrhea (59). In contrast, our
proband has normal cholesterol levels (Table 1) and a phenotype most notable
for congenital diarrhea, cholestasis, persistently elevated liver function tests, and
liver fibrosis (Table 1).

Mouse models of genetic cholestasis do not consistently recapitulate the human
disease phenotype due to differences in tissue gene expression and bile acid
metabolism between mice and humans (25, 60-62). This is clearly demonstrated
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in the OSTα deficient mouse. SLC51A mRNA is abundantly expressed in human
liver whereas minimal to no expression is seen in whole livers of mice and rats
(25). Additionally, two independent OSTα deficient mouse lines available do not
show any liver pathology (63, 64). Although the OSTα-β requires expression of
both subunits for stability and function of the transporter, the relative gene
expression of each subunit does not occur in a 1:1 ratio in several tissues (25).
Notably, in humans, SLC51A mRNA is expressed more abundantly than SLC51B
in the liver (25). Hence, it is interesting that our OSTα deficient proband has a
more severe liver phenotype as compared to liver histological findings reported in
an OSTβ deficient patient (27). Specifically, liver biopsy of one of the OSTβ
deficient patients at age 10 showed that the hepatic lobular architecture was
intact, with a mild degree of portal fibrosis without features of bile retention or bile
duct pathology (27), whereas the liver biopsy of our OSTα deficient child at age 4
showed both bile duct loss and bridging fibrosis and imminent cirrhosis (Figure 4
A, B). Further studies are needed to investigate whether the unique abundance
of hepatic SLC51A transcripts as compared to SLC51B may account for a
predominant and/or additional role(s) of OSTα in the liver, possibly explaining the
difference in liver disease severity seen among human OSTα and OSTβ
deficiency.

It is notable that our proband and the OSTβ deficient siblings have normal or
near-normal serum bile acid levels in the presence of cholestasis. Usually
cholestasis is associated with elevated serum bile levels. One possible
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explanation of this is that there are two opposing effects that lead to normal
plasma levels in OSTα-β deficiency. Failure of bile acid absorption from the gut
may lead to lower blood bile acid concentrations. Decreased bile acid uptake
from the blood by the liver may increase blood bile acid concentrations. The net
effect may result in normal plasma levels seen in these patients.

A limitation of this study is that our proband is the first patient reported to have
OSTα deficiency, and there were only two patients previously reported to have
OSTβ deficiency. With a total of three patients reported to lack the OSTα-β
transporter, it is uncertain whether the observed difference in liver fibrosis is a
true difference between OSTα deficiency and OSTβ deficiency, or whether
overall the transporter deficiency has a highly variable liver presentation,
reflected by the spectrum of disease between the patients. An additional
shortcoming of the study was the absence of antibodies to detect OSTα protein
expression in control samples. Immunostaining for OSTα was attempted on
control slides of liver and intestine, but unsuccessful. We attempted staining with
two antibodies (an in-house antibody and a Santa Cruz N15 sc-100078 antibody)
with two different antigen retrievals (10 mm citrate pH 6, 1 mm EDTA, pH8). The
in-house antibody successfully immunostained OSTα in frozen liver samples in
Ballatori et. al. 2005 (25). However, our proband’s biopsies were formalin-fixed
paraffin-embedded (FFPE) colon and liver tissue. Our in-house antibodies have
never been shown to immunostain FFPE samples, and to our knowledge the
Santa Cruz N15 sc-100078 antibodies have not been shown to stain such
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samples either. In light of this limitation, we extracted mRNA from formalin-fixed
paraffin-embedded (FFPE) colon samples of the proband and the controls and
assessed OSTα and OSTβ expression at the mRNA level. While there is known
variability in the quality of RNA isolated from FFPE samples (65), we consistently
found the absence of SLC51A expression and presence of SLC51B expression
in our proband and the expression of both subunits in our control samples, using
taqman gene expression assays (Figure 9).

Collectively, our findings highlight the importance of using genomic analysis to
study patients with idiopathic disease. Although the SLC51A gene was
discovered in Leucoraja erinacea and subsequently in humans over 15 years
ago, it was not until genomic analysis was applied to children with undiagnosed
liver disease that the first case of human OSTα deficiency was identified. Our
study also shows the utility in studying genetics in highly consanguineous
communities, and in South Asian communities that have been historically
underrepresented in genomics research. Several papers have addressed the
particular promise of conducting research in countries such as Pakistan given
the high rate of consanguinity and the range of biodiversity within this population
(66). The conclusions of our research have enabled us to give a diagnosis to our
proband’s previously idiopathic liver fibrosis and congenital diarrhea. Long-term
follow-up of the proband and the two siblings with OSTβ deficiency (27) as well
as additional patients with these deficiencies is needed to determine the
spectrum of clinical features attributable to loss of function of these transporters.
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Improved understanding of the clinical course and features of OSTα deficiency
through the discovery of additional patients with OSTα–β deficiency may enable
us to offer further prognosis and clinical management for our proband.

In summary, this study provides further evidence on how an unbiased genomic
approach is highly valuable in many areas of biomedicine (46, 67, 68), including
in the field of Hepatology (12-14, 69). In addition to pinpointing the etiology of
diseases that elude standard diagnostic evaluations, whole exome sequencing
has the power to uncover genetic contributions to human health and disease.
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